Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of HRS9531 in Healthy Subjects
NCT05152277Phase 1Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS9531 in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Number of Adverse Events. Started Dec 2021; status: completed.
02
Drugs
HRS9531
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05152277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152277.